<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04027556</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-2019-0344</org_study_id>
    <nct_id>NCT04027556</nct_id>
  </id_info>
  <brief_title>Reducing Iodine Dose Based on Lean Body Weight</brief_title>
  <official_title>Detection of Hepatocellular Carcinomas Using Virtual Monoenergetic Imaging With Reduced Iodine Dose Based on Lean Body Weight</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Siemens Healthineers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess whether the acceptable image quality is achievable using low
      contrast media dose calculated based on lean body weight and low keV imaging for the
      detection of hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, the contrast media dose is calculated based on total body weight. However, the
      human body is composed of adipose tissue and non-adipose tissue, and adipose tissue
      contributes little to the volume of distribution for contrast media. Therefore, iodine dose
      calculated based on lean body weight would be more personalized than merely considering total
      body weight. In addition, lowering the contrast media dose would be achievable by using
      virtual monoenergetic imaging at low keV. Therefore, we aimed to assess whether the
      acceptable image quality is achievable using low contrast media dose calculated based on lean
      body weight and low keV imaging for the detection of hepatocellular carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lesion conspicuity</measure>
    <time_frame>12 months after complete enrollment</time_frame>
    <description>qualitative scoring for focal lesion depiction on five-point scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Image noise</measure>
    <time_frame>12 months after complete enrollment</time_frame>
    <description>qualitative scoring for focal image contrast on four-point scale: 1, poor; 4, good</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Image contrast</measure>
    <time_frame>12 months after complete enrollment</time_frame>
    <description>qualitative scoring for focal image contrast on four-point scale: 1, poor; 4, good</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall image quality: four-point scale</measure>
    <time_frame>6 months after complete enrollment</time_frame>
    <description>qualitative scoring for focal image contrast on four-point scale: 1, poor; 5, good</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion detection</measure>
    <time_frame>12 months after complete enrollment</time_frame>
    <description>assessment of focal liver lesion (HCC) on CT according to Liver Imaging Reporting and Data System (LI-RADS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hounsfield unit</measure>
    <time_frame>3 months after complete enrollment</time_frame>
    <description>measurement of hounsfield unit in aorta, portal vein, liver parenchyma, and paraspinal muscles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast media dose</measure>
    <time_frame>3 months after complete enrollment</time_frame>
    <description>administered contrast media dose in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation dose</measure>
    <time_frame>3 months after complete enrollment</time_frame>
    <description>measured radiation dose in each group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Body Weight</condition>
  <arm_group>
    <arm_group_label>Low dose - lean body weight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low CT contrast media dose calculated based on lean body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard CT contrast media dose calculated based on total body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>low dose CT contrast media - lean body weight</intervention_name>
    <description>CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 450mgI/kg based on lean body weight.</description>
    <arm_group_label>Low dose - lean body weight</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard dose CT contrast media</intervention_name>
    <description>CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 560mgI/kg based on total body weight.</description>
    <arm_group_label>Standard dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High risk group for developing HCC

          -  Scheduled contrast-enhanced CT for HCC diagnosis or surveillance

        Exclusion Criteria:

          -  not a high risk group for developing HCC

          -  body mass index is equal to or larger than 30 kg/m^2

          -  suspected HCC &gt; 5cm in diameter

          -  received locoregional treatment or surgery for HCC within 3 months

          -  congestive hepatopathy

          -  no venous access on forearm

          -  anticipated beam hardening artifact due to prosthesis

          -  relative/absolute contraindication of contrast-enhanced CT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun Hee Lee, RN</last_name>
    <phone>82-2-2072-4177</phone>
    <email>redlion55@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jae Seok Bae, MD</last_name>
    <phone>82-2-2072-1465</phone>
    <email>jaeseok.bae@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeong Min Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 18, 2019</study_first_submitted>
  <study_first_submitted_qc>July 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2019</study_first_posted>
  <last_update_submitted>July 19, 2019</last_update_submitted>
  <last_update_submitted_qc>July 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

